Evotec SE simplified its structure and reduced staff in the first half of 2024 in response to a slowdown in its traditional drug services business. At the same time, there was an increase in its newer biologics manufacturing business with the result that group revenue rose by 2% to €390.8 million compared with €383.8 million a year earlier. Revenue from the service business, which accounts for 77% of total turnover, was down by 7% but income from biologics manufacturing was up by 50%.
